It appears that Catalyst Health Ventures, an investor in early stage healthcare companies, is looking to raise a new fund.
The firm disclosed a $33 million securities offering — with the first sale yet to occur — in a recently filed U.S. Securities and Exchange Commission document.
Managing partner Joshua Phillips declined to comment on plans for the fund, but according to Catalyst’s website, it focuses its investments in technologically advanced medical devices, diagnostics, instruments and drug development. Typically, the firm invests early and takes the lead on investments.
Portfolio companies include GI Dynamics Inc., Hansen Medical Inc. (NASDAQ:HNSN), Novazyme Pharmaceuticals (acquired by Genzyme in 2001) and 3-D scanning firm Lantos Technologies. Catalyst has also contributed to medical technology incubators Pavilion Medical Innovations and Seedling Enterprises.
Located in Boston, Catalyst concentrates its investments in the northeastern U.S.
By Deanna Pogorelc MedCity News
Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.More posts by Author
Onciomed, Inc is based out of Irvine, Ca has a novel medical device technology to treat obesity and diabetes.
The company has great animal data, completed 1st in human OUS, pursuing a clinical study of 30 Pts outside US. Onciomed, Inc is raising Series A capital in 2012.
www.onciomed.com